About the company

Oxymend™ is an oxygen wound therapy device developed by a team of doctors, engineers, and former biotech and medtech entrepreneurs experienced in taking products from initial conception to the global market. We have partnered with the University of Toledo to develop, manufacture and conduct efficacy studies. We are dedicated to developing products that are clinically driven and centered around improving the outcome for the patient.

Our Mission

The number of patients with chronic wounds has increased over the past several decades alongside a dramatic increase in type 2 diabetes. NCBI estimates 2% of the total population of developed nations will experience a chronic wound in their lifetime. Diabetic Foot Ulcers (DFUs) progress quickly to problem wounds due to microvascular changes associated with diabetes. They are notoriously difficult to treat. Poor blood circulation compromises oxygen flow and, as a result, can quickly become infected. Ultimately, wounds that are not able to heal are treated by amputation. Annual incidences of foot ulcers among people with diabetes are approximately 7%, and annual incidences of amputation resulting from these wounds are approximately 0.25% to 1.8%. Untreated, or poorly treated wounds are unfortunately prevalent, leading to costly procedures, hospitalizations, and a need for rehabilitation. Oxymend™ aims to provide patients with chronic wounds greater access to care by developing an affordable, wearable, efficacious, miniaturized oxygen production and delivery dressing - outperforming Hyperbaric Oxygen Therapy in a device that could fit in your pocket.

Our Team

  • Chandan Das, MD


    Holds an MD from UAMS, and is currently a surgical resident at University of Toledo. Dr. Das also holds a degree in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) and is a Howard Hughes Medical Institute (HHMI) Scholar.
  • Trygve Burchardt, PhD


    Has nearly two decades of experience as a C-level executive, most recently, CTO at Biim Ultrasound. He has a PhD in chemistry from the University of Oslo (UiO). Raised more than $30M in VC funding / grants. Holds several patents and publications.
  • Kundan Das


    Founded a biotech company during his freshman year in college developing novel assay technologies for redox researchers and before his senior year had raised seed capital to develop the world's largest life sciences marketplace.
  • Thomas E. Serena, MD


    Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies.